{
    "eid": "2-s2.0-85160635419",
    "title": "Safinamide as an Adjunct to Levodopa in Asian and Caucasian Patients With Parkinson\u2019s Disease and Motor Fluctuations: A Post Hoc Analysis of the SETTLE Study",
    "cover-date": "2023-05-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Neurology",
            "@code": "2808",
            "@abbrev": "NEUR"
        },
        {
            "@_fa": "true",
            "$": "Neurology (clinical)",
            "@code": "2728",
            "@abbrev": "MEDI"
        }
    ],
    "keywords": [
        "aaAsian",
        "MAO-B inhibitor",
        "Motor fluctuation",
        "Parkinson\u2019s disease",
        "Randomized clinical trial",
        "Safinamide"
    ],
    "authors": [
        "Roongroj Bhidayasiri",
        "Takayuki Ishida",
        "Takanori Kamei",
        "Ryan Edbert Husni",
        "Ippei Suzuki",
        "Shey Lin Wu",
        "Jin Whan Cho"
    ],
    "citedby-count": 0,
    "ref-count": 38,
    "ref-list": [
        "Prevalence of wearing-off and dyskinesia among the patients with Parkinson\u2019s disease on levodopa therapy: a multi-center registry survey in mainland China",
        "Dyskinesias and motor fluctuations in Parkinson\u2019s disease. A community-based study",
        "Parkinson\u2019s disease and its management: part 4: treatment of motor complications",
        "Levodopa: a new look at an old friend",
        "Parkinson\u2019s disease in the Western Pacific Region",
        "New treatments for levodopa-induced motor complications",
        "Safinamide differentially modulates in vivo glutamate and GABA release in the rat hippocampus and basal ganglia",
        "Biochemical and electrophysiological studies on the mechanism of action of PNU-151774E, a novel antiepileptic compound",
        "Randomized trial of safinamide add-on to levodopa in Parkinson\u2019s disease with motor fluctuations",
        "Two-year, randomized, controlled study of safinamide as add-on to levodopa in mid to late Parkinson\u2019s disease",
        "Efficacy and safety of safinamide as an add-on therapy to L-DOPA for patients with Parkinson\u2019s disease: a randomized, doubleblind, placebo-controlled, phase II/III study",
        "Assessment of safety and efficacy of safinamide as a levodopa adjunct in patients with Parkinson disease and motor fluctuations: a randomized clinical trial",
        "The XINDI study: a randomized phase III clinical trial evaluating the efficacy and safety of safinamide as add-on therapy to levodopa in Chinese patients with Parkinson\u2019s disease with motor fluctuations",
        "International Parkinson and movement disorder society evidence-based medicine review: update on treatments for the motor symptoms of Parkinson\u2019s disease",
        "Efficacy and safety evaluation of safinamide as an add-on treatment to levodopa for Parkinson\u2019s disease",
        "Association of COMT rs4680 and MAO-B rs1799836 polymorphisms with levodopa-induced dyskinesia in Parkinson\u2019s disease-a meta-analysis",
        "Association of catechol-O-methyltransferase gene rs4680 polymorphism and levodopa induced dyskinesia in Parkinson\u2019s disease: a meta-analysis and systematic review",
        "Polymorphisms of the dopamine metabolic and signaling pathways are associated with susceptibility to motor levodopa-induced complications (MLIC) in Parkinson\u2019s disease: a systematic review and meta-analysis",
        "Impact of ethnicity on non-motor symptoms of Parkinson\u2019s disease",
        "Variations in the patterns of prevalence and therapy in Australasian Parkinson\u2019s disease patients of different ethnicities",
        "Asian perspectives on the recognition and management of levodopa \u2018wearing-off\u2019 in Parkinson\u2019s disease",
        "Features of anticholinergic prescriptions and predictors of high use in the elderly: population-based study",
        "The clinically important difference on the unified Parkinson\u2019s disease rating scale",
        "Female, aging, difference formulations of DCI, or lower body weight in creases AUC4hr of levodopa in patients with Parkinson\u2019s disease",
        "Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson\u2019s disease",
        "Amantadine treatment and delayed onset of levodopa-induced dyskinesia in patients with early Parkinson\u2019s disease",
        "Long-term effects of safinamide adjunct therapy on levodopa-induced dyskinesia in Parkinson\u2019s disease: post-hoc analysis of a Japanese phase III study",
        "Impact of ethnicity on the natural history of Parkinson disease",
        "Nonmotor symptoms in Parkinson\u2019s disease: gender and ethnic differences",
        "Effects of safinamide on non-motor, cognitive, and behavioral symptoms in fluctuating Parkinson\u2019s disease patients: a prospective longitudinal study",
        "Safinamide improves executive functions in fluctuating Parkinson\u2019s disease patients: an exploratory study",
        "Anticholinergics for symptomatic management of Parkinson\u2019s disease",
        "Patterns and determinants of prescribing for Parkinson\u2019s disease: a systematic literature review",
        "The EQ-5D--a generic quality of life measure-is a useful instrument to measure quality of life in patients with Parkinson\u2019s disease",
        "Determining minimally important differences for the PDQ-39 Parkinson\u2019s disease questionnaire",
        "Non-motor symptoms assessed by non-motor symptoms questionnaire and non-motor symptoms scale in Parkinson\u2019s disease in selected Asian populations",
        "Functional polymorphisms of the MAO gene with Parkinson disease susceptibility: a meta-analysis",
        "Characteristics of wearing-off and motor symptoms improved by safinamide adjunct therapy in patients with Parkinson\u2019s disease: a post hoc analysis of a Japanese phase 2/3 study"
    ],
    "affiliation": [
        {
            "affiliation-city": "Tokyo",
            "@id": "60018508",
            "affilname": "Eisai Co., Ltd.",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60018508",
            "affiliation-country": "Japan"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60022183",
            "affilname": "King Chulalongkorn Memorial Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60022183",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Changhua",
            "@id": "60022174",
            "affilname": "Changhua Christian Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60022174",
            "affiliation-country": "Taiwan"
        },
        {
            "affiliation-city": "Seoul",
            "@id": "60020857",
            "affilname": "Samsung Medical Center, Sungkyunkwan university",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60020857",
            "affiliation-country": "South Korea"
        },
        {
            "affiliation-city": "Suwon",
            "@id": "60016329",
            "affilname": "SKKU School of Medicine",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60016329",
            "affiliation-country": "South Korea"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "106208652",
            "affilname": "Academy of Science",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/106208652",
            "affiliation-country": "Thailand"
        }
    ],
    "funding": [
        "AMICULUM Asia",
        "Newron Pharmaceuticals",
        "Merck Serono",
        "Eisai Co. Ltd."
    ]
}